Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

STAA - Staar Surgical Co.


IEX Last Trade
33.085
0.945   2.856%

Share volume: 601,829
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST

PREVIOUS CLOSE
CHG
CHG%

$32.14
0.95
2.94%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Company vs Stock growth
vs
Performance
5 Days
-0.54%
1 Month
-17.67%
3 Months
-18.50%
6 Months
4.85%
1 Year
-24.81%
2 Year
-65.23%
Key data
Stock price
$33.08
P/E Ratio 
97.97
DAY RANGE
N/A - N/A
EPS 
$0.34
52 WEEK RANGE
$26.66 - $52.68
52 WEEK CHANGE
-$0.23
MARKET CAP 
1.628 B
YIELD 
N/A
SHARES OUTSTANDING 
49.188 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
1.61
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$674,618
AVERAGE 30 VOLUME 
$963,448
Company detail
CEO: Caren Mason
Region: US
Website: http://staar.com/
Employees: 644
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl"​. nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad

Recent news